CDC25A and head and neck squamous cell carcinoma: Comparable frequency of SH3GL2 deletion (30–46%) was observed in subsequent stages, while deletion frequencies of CDC25A (37–41%) were comparable upto stage-I/II followed by significant increase (61–64%) in stage-III/IV of the HNSCC samples (Figure 3f, Figure S4).